Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
January 12, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with...
PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China
January 11, 2022 07:15 ET
|
Pacific Biosciences of California, Inc.
New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China Berry Genomics to purchase at least 50 instruments at product...
PacBio Announces Collaboration with Genomics England to Sequence Biobanked Rare Disease Samples Using HiFi Sequencing Technology
January 11, 2022 07:10 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics...
PacBio and Google Collaborate to Use Machine Learning to Optimize Long-Read Sequencing Data Analysis
January 11, 2022 07:05 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced a research collaboration with...
PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations
January 11, 2022 07:00 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue...
Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones
January 10, 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million 2022 Crysvita revenue in Ultragenyx territories expected...
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...